Elmind Capital LP purchased a new position in Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 120,000 shares of the company's stock, valued at approximately $4,416,000,000. Urogen Pharma makes up about 1.1% of Elmind Capital LP's portfolio, making the stock its 22nd biggest holding. Elmind Capital LP owned approximately 0.25% of Urogen Pharma as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. ADAR1 Capital Management LLC purchased a new stake in Urogen Pharma during the 2nd quarter worth approximately $9,288,000. Parkman Healthcare Partners LLC purchased a new position in shares of Urogen Pharma during the 2nd quarter valued at approximately $6,406,000. Legal & General Group Plc purchased a new position in shares of Urogen Pharma during the 2nd quarter valued at approximately $1,319,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Urogen Pharma during the second quarter worth approximately $412,000. Finally, Partners Capital Investment Group LLP acquired a new stake in shares of Urogen Pharma during the second quarter worth approximately $566,000. Hedge funds and other institutional investors own 91.29% of the company's stock.
Urogen Pharma Price Performance
Shares of URGN opened at $46.36 on Wednesday. The business's fifty day moving average price is $41.11 and its 200 day moving average price is $29.51. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81. The stock has a market capitalization of $2.27 billion, a PE ratio of -23.41 and a beta of 1.57.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to analysts' expectations of $63.55 million. As a group, research analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.
Insider Activity at Urogen Pharma
In other news, insider Mark Schoenberg sold 60,677 shares of Urogen Pharma stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85. Following the completion of the transaction, the insider directly owned 59,086 shares of the company's stock, valued at approximately $2,779,996.30. The trade was a 50.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 85,899 shares of company stock valued at $3,747,513. Insiders own 4.80% of the company's stock.
Wall Street Analysts Forecast Growth
URGN has been the topic of several recent analyst reports. UBS Group reaffirmed a "buy" rating on shares of Urogen Pharma in a report on Thursday, July 9th. The Goldman Sachs Group reissued a "neutral" rating and issued a $44.00 target price on shares of Urogen Pharma in a research report on Wednesday, July 15th. Guggenheim upped their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Urogen Pharma in a research report on Friday, July 17th. Finally, HC Wainwright lifted their price target on Urogen Pharma from $45.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.38.
Check Out Our Latest Analysis on Urogen Pharma
About Urogen Pharma
(
Free Report)
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Featured Articles
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma (NASDAQ:URGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
